CTOs on the Move

Entelo

www.entelo.com

 
Entelo applies intelligence to big data to help modern recruiters identify, qualify and engage talent. Today, more than 700 customers of all sizes and industries trust Entelo to provide their talent acquisition teams with higher candidate engagement, actionable insights and increased productivity. The leader in recruiting automation, Entelo helps organizations like Capital One, Cisco, GE, Genentech, Netflix, Northrop Grumman and Target build their teams.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.entelo.com
  • 123 Mission Street 24th Floor
    San Francisco, CA USA 94105
  • Phone: 415.689.7774

Executives

Name Title Contact Details
Andrew Schafer
 Chief Technology Officer Profile

Funding

Entelo raised $20M on 06/15/2017

Similar Companies

Myriad RBM

Myriad RBM is a Austin, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CardioVascular BioTherapeutics

CardioVascular BioTherapeutics, Inc. is a Las Vegas, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Skingenix

Skingenix is a Arcadia, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Zymergen

Founded in 2013 and based in the San Francisco Bay Area, Zymergen integrates automation, machine learning, and genomics to rapidly accelerate the pace of scientific advancement. We treat the genome as a search space, leveraging machine learning to make discoveries far beyond the bounds of human intuition. In doing so, we deliver economic value, material diversity and performance capabilities not previously possible.

Immunovant

Immunovant is a biopharmaceutical company committed to developing innovative therapies that not only treat the symptoms, but modify the course of autoimmune diseases. Our primary investigational product candidate is RVT-1401, a human recombinant anti-FcRn monoclonal antibody that is being developed with a focus on patient need, and may be applicable to a wide array of autoimmune diseases. We are currently assessing RVT-1401 in a single and multiple ascending dose Phase 1 clinical trial. We plan on initiating a number of patient-based studies in early 2019, focusing on Myasthenia gravis (MG) and other IgG-mediated diseases. We also seek to continue expanding our pipeline, ultimately transforming the lives of patients with autoimmune diseases.